Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Rheumatology · Undifferentiated Connective Tissue Disease

What Do UCTD Antibodies Mean? Anti-Ro, Anti-La & More

At a Glance

In UCTD, specific antibodies are clues rather than diagnoses. Anti-Ro, anti-La, anti-RNP, anti-Sm, anti-Scl-70, and anticentromere results are interpreted with symptoms and examination to plan individualized monitoring, including pregnancy and organ checks.

A positive antibody result on your lab report can be unsettling, but it is just one piece of the puzzle and does not determine your future by itself. In Undifferentiated Connective Tissue Disease (UCTD), autoantibodies act as biological signposts. They do not prove that you have, or are guaranteed to develop, another specific autoimmune disease. Instead, they guide your care team on exactly which symptoms to watch for and which organs to monitor [1].

While studies tracking UCTD patients over 5 to 7 years show that roughly 20% to 28% may evolve to a defined connective tissue disease, this is a research average, not your individual risk [1][2]. How these antibodies are interpreted depends heavily on your physical exam, your specific symptoms, the level (titer) of the antibodies, and even the specific testing method used, as false positives can occur [1][3].

Summary of Autoantibodies in UCTD

Antibody May Be Associated With What to Monitor For Important Context
Anti-Ro/SSA & Anti-La/SSB Sjögren’s disease, Neonatal lupus Dry eyes/mouth, fetal heart health (if pregnant) Does not guarantee Sjögren’s; requires clinical evaluation
Anti-Sm & Anti-dsDNA Lupus (SLE) Kidney function, blood counts, complement levels Kidney monitoring includes blood pressure and urine tests
Anti-Scl-70 & Anticentromere Systemic Sclerosis Lung function, heart health, Raynaud’s Testing is individualized based on physical symptoms
Anti-RNP MCTD, Lupus Overlap symptoms (swollen hands, muscle weakness) Found in multiple conditions; MCTD requires specific clinical criteria

Anti-Ro/SSA and Anti-La/SSB: Sjögren’s and Pregnancy

Sjögren’s Disease Risk
Anti-Ro (also called SSA) and anti-La (SSB) are frequently associated with Sjögren’s disease [1][4]. If you have these antibodies alongside dry eyes or a dry mouth, your doctor may perform a focused evaluation. For example, an abnormal Schirmer test (a simple paper-strip test measuring tear production) combined with these antibodies warrants investigation for Sjögren’s, but it is important to remember that dryness can also be caused by certain medications or other common factors [1].

Pregnancy Considerations
These antibodies are critical to discuss if you plan to become pregnant, as both can cross the placenta [5][6]. In about 1% to 2% of first-time pregnancies in people with these antibodies, they can cause congenital heart block, a permanent disruption of the baby’s heart rhythm that often requires a pacemaker [7]. If you have had a prior child with congenital heart block, the risk in future pregnancies is higher (around 12% to 25%) [5]. Other temporary effects, like newborn rashes (neonatal lupus), can also occur but typically resolve as maternal antibodies clear [7].

If you carry these antibodies, it is essential to arrange preconception counseling with your rheumatologist and a high-risk obstetrician [6]. Do not stop or change any medications without medical advice. If you become pregnant, monitoring guidelines vary, but your team may recommend specialized surveillance, such as serial fetal echocardiograms (ultrasounds of the baby’s heart) between gestational weeks 16 and 24 [8][9].

Anti-Sm and Anti-dsDNA: Lupus Risk

Anti-Sm (Smith) and anti-dsDNA (anti-double-stranded DNA) antibodies are strongly linked to Systemic Lupus Erythematosus (SLE) [10][11]. Having these in your blood suggests your doctor should closely monitor you for signs of lupus. Because lupus can affect the kidneys and blood cells, practical monitoring includes checking your blood pressure, serum creatinine (a kidney function blood test), and urine protein levels [12]. Your care team will also regularly check your blood counts and complement levels (C3 and C4, which are immune system proteins that often drop during active lupus) [10].

Anti-Scl-70 and Anticentromere: Systemic Sclerosis Risk

Anti-Scl-70 (anti-topoisomerase I) and anticentromere antibodies indicate a risk for systemic sclerosis (scleroderma) [11][13]. If you have these, your doctor will pay special attention to:

  • Raynaud’s phenomenon: A condition where fingers or toes turn white, blue, and then red in response to cold or stress [14].
  • Puffy fingers or skin thickening: Swelling or hardening of the skin [11].
  • Nailfold capillaroscopy: A painless, routine exam where a doctor uses a magnifying tool to look at the tiny blood vessels (capillaries) at the base of your fingernails. Abnormalities here can be an early warning sign [11][15].

Depending on your symptoms, your doctor may order pulmonary function tests (breathing tests) to check for interstitial lung disease, or an echocardiogram (ultrasound of the heart) to check for pulmonary hypertension [16][17]. These tests are highly individualized and are not automatically required for every patient who simply has the antibody.

Anti-RNP: Mixed Connective Tissue Features

High levels of anti-U1-RNP may prompt your doctor to evaluate you for Mixed Connective Tissue Disease (MCTD) [18]. MCTD is a specific clinical diagnosis involving a combination of lupus, scleroderma, and muscle inflammation symptoms. However, anti-RNP is also found in lupus and other connective tissue diseases, meaning the antibody alone cannot diagnose MCTD [19]. It simply alerts your doctor to watch for overlapping physical symptoms like swollen hands, Raynaud’s phenomenon, or muscle weakness [19].

What This Means for Your Care

There is no single fixed schedule for UCTD follow-ups; your visit frequency and laboratory tests will depend on your specific symptoms, disease activity, and pregnancy plans [20][10].

To help manage your care, it is important to separate routine symptoms from those requiring immediate attention:

  • Urgent Symptoms (Seek immediate medical care): Severe shortness of breath, new chest pain, fainting, markedly high blood pressure, suddenly reduced urine, or foamy/bloody urine.
  • Routine Symptoms (Mention at your next appointment): Worsening dry eyes, mild joint swelling, new skin rashes, or increased color changes in your fingers.

Common questions in this guide

Can one positive antibody tell me which autoimmune disease I have?
No. A positive antibody is one clue and does not by itself prove that you have lupus, Sjögren's disease, systemic sclerosis, or mixed connective tissue disease. Your clinician interprets it with your symptoms, examination, antibody level, and the testing method.
Does anti-Ro or anti-La automatically mean I have Sjögren's disease?
No. Anti-Ro/SSA and anti-La/SSB are often associated with Sjögren's disease, but many people with these antibodies do not have Sjögren's. Dry eyes or a dry mouth may lead to further evaluation, such as a Schirmer test that measures tear production, while medication and other causes of dryness are also considered.
Why do anti-Ro and anti-La matter during pregnancy?
If you are pregnant or planning pregnancy, anti-Ro/SSA and anti-La/SSB should be discussed with your rheumatologist and a high-risk obstetrician because they can cross the placenta. In about 1% to 2% of first pregnancies in people with these antibodies, they can cause congenital heart block, and the risk is higher after a prior affected child. Your team may recommend fetal heart ultrasound monitoring from 16 to 24 weeks, and you should not change medicines without medical advice.
How are anti-Sm and anti-dsDNA used when lupus is a concern?
Anti-Sm and anti-dsDNA are strongly associated with lupus, but an antibody result alone does not establish that diagnosis. If these antibodies are present, monitoring may include blood pressure, kidney function, urine protein, blood counts, and immune proteins called complement levels.
What could anti-Scl-70 or anticentromere antibodies mean?
Anti-Scl-70 and anticentromere antibodies can be associated with systemic sclerosis, but they do not make the diagnosis on their own. Your clinician may ask about Raynaud's color changes, puffy fingers, or thickened skin and order breathing or heart tests when your symptoms and examination indicate them.
Can anti-RNP alone diagnose mixed connective tissue disease?
No. Anti-RNP can occur in mixed connective tissue disease, lupus, and other connective tissue diseases. A high level may prompt evaluation for overlapping features such as swollen hands, Raynaud's phenomenon, or muscle weakness, but mixed connective tissue disease requires a clinical diagnosis.
Which symptoms need urgent medical attention?
Seek immediate medical care for severe shortness of breath, new chest pain, fainting, markedly high blood pressure, suddenly reduced urine, or foamy or bloody urine. Milder changes such as worsening dry eyes, mild joint swelling, new rashes, or more finger color changes should be reported to your clinician at a routine visit or sooner if advised.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Undifferentiated connective tissue syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific antibodies are positive in my report, at what levels, and what does that change about my monitoring?
  2. 2.Given my antibody profile, what baseline tests (like a urine protein check, breathing tests, or an echocardiogram) do you recommend right now, if any?
  3. 3.What is our plan for preconception counseling, and which of my current medications are safe if I decide to become pregnant in the future?
  4. 4.How often should we schedule my routine follow-up visits and lab work based on my overall disease activity?
  5. 5.Are there any specific symptoms based on my antibody profile that should prompt me to call the office before my next scheduled visit?

References

References (20)
  1. 1

    Can baseline features predict progression to defined connective tissue disease? Insights from a minimum 5-year follow-up study of 504 patients with undifferentiated connective tissue disease: A retrospective study.

    Apaydin H, Sağirkaya ŞÇ, Polat B, et al.

    Modern rheumatology 2026; (36(4)):619-626 doi:10.1093/mr/roag006.

    PMID: 41670330
  2. 2

    Undifferentiated Connective Tissue Disease: Comprehensive Review.

    Rubio J, Kyttaris VC

    Current rheumatology reports 2023; (25(5)):98-106 doi:10.1007/s11926-023-01099-5.

    PMID: 36884206
  3. 3

    Comparison of antibody assays for detection of autoantibodies to Ro 52, Ro 60 and La associated with primary Sjögren's syndrome.

    Trier NH, Nielsen IØ, Friis T, et al.

    Journal of immunological methods 2016; (433()):44-50.

    PMID: 26956184
  4. 4

    Prognostic value of Sjögren's syndrome autoantibodies.

    Scofield RH, Fayyaz A, Kurien BT, Koelsch KA

    Journal of laboratory and precision medicine 2018; (3()) doi:10.21037/jlpm.2018.08.05.

    PMID: 32090197
  5. 5

    Congenital heart block: Pace earlier (Childhood) than later (Adulthood).

    Manolis AA, Manolis TA, Melita H, Manolis AS

    Trends in cardiovascular medicine 2020; (30(5)):275-286 doi:10.1016/j.tcm.2019.06.006.

    PMID: 31262557
  6. 6

    2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

    Sammaritano LR, Bermas BL, Chakravarty EE, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2020; (72(4)):529-556 doi:10.1002/art.41191.

    PMID: 32090480
  7. 7

    Neonatal lupus erythematosus - practical guidelines.

    Derdulska JM, Rudnicka L, Szykut-Badaczewska A, et al.

    Journal of perinatal medicine 2021; (49(5)):529-538 doi:10.1515/jpm-2020-0543.

    PMID: 33470961
  8. 8

    Autoimmune Congenital Heart Block: A Review of Biomarkers and Management of Pregnancy.

    De Carolis S, Garufi C, Garufi E, et al.

    Frontiers in pediatrics 2020; (8()):607515 doi:10.3389/fped.2020.607515.

    PMID: 33415090
  9. 9

    Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.

    , Silver R, Craigo S, et al.

    American journal of obstetrics and gynecology 2023; (228(3)):B41-B60 doi:10.1016/j.ajog.2022.09.001.

    PMID: 36084704
  10. 10

    Evolutionary trajectory of undifferentiated connective tissue disease and impact of 2019 EULAR/ACR systemic lupus erythematosus classification criteria: insights from a longitudinal study.

    Ciancarella C, Ceccarelli F, Picciariello L, et al.

    Clinical and experimental medicine 2025; (25(1)):134 doi:10.1007/s10238-025-01668-1.

    PMID: 40310587
  11. 11

    Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: A systematic review and meta-analysis.

    Dyball S, Rodziewicz M, Mendoza-Pinto C, et al.

    Autoimmunity reviews 2022; (21(11)):103184 doi:10.1016/j.autrev.2022.103184.

    PMID: 36031048
  12. 12

    Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease.

    Radin M, Schreiber K, Cecchi I, et al.

    Arthritis care & research 2021; (73(12)):1804-1808 doi:10.1002/acr.24391.

    PMID: 32702197
  13. 13

    Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.

    Cavazzana I, Vojinovic T, Airo' P, et al.

    Clinical reviews in allergy & immunology 2023; (64(3)):412-430 doi:10.1007/s12016-022-08946-w.

    PMID: 35716254
  14. 14

    Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?

    Valentini G, Pope JE

    Autoimmunity reviews 2020; (19(11)):102659 doi:10.1016/j.autrev.2020.102659.

    PMID: 32942034
  15. 15

    Nailfold capillaroscopy.

    Smith V, Ickinger C, Hysa E, et al.

    Best practice & research. Clinical rheumatology 2023; (37(1)):101849 doi:10.1016/j.berh.2023.101849.

    PMID: 37419757
  16. 16

    Correlation study between clinical phenotypes and autoantibodies in systemic sclerosis in Southwest China.

    Sui J, Li H, Liu Y, et al.

    Medicine 2025; (104(23)):e42639 doi:10.1097/MD.0000000000042639.

    PMID: 40489831
  17. 17

    Lung involvement in "stable" undifferentiated connective tissue diseases: a rheumatology perspective.

    Riccardi A, Irace R, Di Stefano I, et al.

    Clinical rheumatology 2017; (36(8)):1833-1837 doi:10.1007/s10067-017-3704-8.

    PMID: 28597132
  18. 18

    Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives.

    Ferrara CA, La Rocca G, Ielo G, et al.

    ImmunoTargets and therapy 2023; (12()):79-89 doi:10.2147/ITT.S390023.

    PMID: 37525698
  19. 19

    The diagnostic challenge of patients with anti-U1-RNP antibodies.

    Elhani I, Khoy K, Mariotte D, et al.

    Rheumatology international 2023; (43(3)):509-521 doi:10.1007/s00296-022-05161-w.

    PMID: 35896805
  20. 20

    Undifferentiated connective tissue disease: state of the art on clinical practice guidelines.

    Antunes M, Scirè CA, Talarico R, et al.

    RMD open 2018; (4(Suppl 1)):e000786 doi:10.1136/rmdopen-2018-000786.

    PMID: 30886731

This page explains how specific antibody results may guide UCTD monitoring for informational purposes only and does not constitute medical advice. Your rheumatologist and, when relevant, maternal-fetal medicine specialist should interpret your results and pregnancy plan.